Cas No.: | 150322-43-3 |
Chemical Name: | Prasugrel |
Synonyms: | Prasugrel;5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate;Acetic acid 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl ester;CS 747;Ethanone, 2-(2-(acetyloxy)-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-1-cyclopropyl-2-(2-fluorophenyl)-;Prasugrel [INN];C20H20FNO3S;Prasugrel (base);Prasugrel base; Effient;Unii-34K66tbt99;CS-747;Efient;LY640315;2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone;Ly-640315;prasugren;Prasugrel Unii-34K66tbt99 |
SMILES: | CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3C(F)=CC=CC=3)C(=O)C4CC4 |
Formula: | C20H20FNO3S |
M.Wt: | 373.44 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Prasugrel is a platelet inhibitor with IC50 value of 1.8 μM.Prasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI. Prasugrel reduces the aggregation ("clumping") of platelets by irreversibly binding to P2Y12 receptors. In rat platelets, prasugrel AM inhibited in vitro platelet aggregation induced by ADP (10 μm) with an IC50 value of 1.8 μm. From Wikipedia |
Target: | P2Y12 receptor |
References: | [1]. Pharmacokinetic basis of the antiplatelet action of prasugrel By Schroer, Karsten; Siller-Matula, Jolanta M.; Huber, Kurt From Fundamental & Clinical Pharmacology (2012), 26(1), 39-46. [2]. Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats By Sugidachi, Atsuhiro; Yamaguchi, Shinji; Jakubowski, Joseph A.; Ohno, Kosaku; Tomizawa, Atsuyuki; Hashimoto, Masami; Niitsu, Yoichi From Journal of Cardiovascular Pharmacology (2011), 58(3), 329-334. [3]. Darius H.Prasugrel.Hamostaseologie. 2012 Aug 1;32(3):186-90. [4]. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P.Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.J Am Coll Cardiol. 2012 Jul 17;60(3):193-9. [5]. Spiel AO, Derhaschnig U, Schwameis M, Bartko J, Siller-Matula JM, Jilma B.Effects of prasugrel on platelet inhibition during systemic endotoxaemia: a randomized controlled trial.Clin Sci (Lond). 2012 Nov 1;123(10):591-600. |